Technique changes risk factors

Article

Fs-laser cataract surgeons cautioned about capsular block syndrome.

However, by maintaining awareness of the changes in the intraocular environment and adopting modifications in their technique, surgeons performing laser cataract surgery can reduce or even eliminate the likelihood of experiencing a case of capsular block syndrome, said Dr Lawless, medical director, Vision Eye Institute, Chatswood, New South Wales, Australia.

Dr Lawless reviewed the development of capsular block syndrome in two eyes that were among the first 50 laser cataract surgery cases performed at the Vision Eye Institute, Sydney, Australia. Both cases occurred on the same day in the hands of a colleague who Dr Lawless described as an experienced and skilled cataract surgeon.

"Different gas patterns are produced within the lens when using the femtosecond laser for capsulotomy and lens fragmentation, but when the nucleus is dense, the gas tends to accumulate behind the nucleus," Dr Lawless said. "The perfect capsulotomy created using the femtosecond laser results in a tight barrier to fluid egress during hydrodissection. These conditions, together with the fact that hydrodissection is usually done quite vigorously in eyes with a dense nucleus, create a perfect storm for blowing out the posterior capsule.

"After these two events, we fully investigated the complications and reported them to the FDA and Australian regulatory agency authorities," he said. "We have also reported our experience in the literature1, and we hope that by reporting on the complication it won't happen to other surgeons. It has not happened in our hands since these first two cases."

Dr Lawless presented a video from the first case that showed the lens fragmentation was performed with what had become routine settings so that its limits were 1 mm anterior to the posterior capsule and 0.5 mm posterior to the anterior capsule.

After the patient was transferred to the operating room, the corneal incisions were opened, ophthalmic viscoelastic device (OVD) was injected into the anterior chamber, which deepened normally, and the capsular disc was removed. There was no evidence of an anterior capsular tear.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.